Literature DB >> 8077665

CD8+ T lymphocyte-mediated antiviral immunity in mice as a result of injection of recombinant viral proteins.

G Weidt1, O Utermöhlen, J Zerrahn, J Reimann, W Deppert, F Lehmann-Grube.   

Abstract

A major portion of the nucleoprotein (amino acids 67 through 300) and the glycoprotein-2 of lymphocytic choriomeningitis (LCM) virus were synthesized by using recombinant technology and were injected together with SDS twice in portions of 5 micrograms into BALB/c mice. As evidenced by diminished replication of LCM challenge virus, both proteins induced antiviral immunity, which was comparable in extent with the immunity caused by infection with LCM vaccinia recombinant viruses. Primed LCM-viral CTLs could not be demonstrated in these mice by culturing splenocytes in the presence of LCM virus, and Abs appeared slowly and in low quantities; but, after injection of large infectious doses, CTLs appeared faster and in higher numbers than in mice not previously treated with viral proteins. Depletion of CD8+ cells, but not of CD4+ cells, by treatment of mice with mAb abolished the antiviral immunity, demonstrating that protection was mediated by CD8+ T lymphocytes. Absence of CD4+ T lymphocytes before and during the period of immunization did not measurably affect the animals' antiviral immune status, indicating that activation of the CD8+ T lymphocytes was not dependent on help by CD4+ cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8077665

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Emergence of virus escape mutants after immunization with epitope vaccine.

Authors:  G Weidt; W Deppert; O Utermöhlen; J Heukeshoven; F Lehmann-Grube
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

2.  DNA vaccination against persistent viral infection.

Authors:  L P Martins; L L Lau; M S Asano; R Ahmed
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

3.  Antiviral protective immunity induced by major histocompatibility complex class I molecule-restricted viral T-lymphocyte epitopes inserted in various positions in immunologically self and nonself proteins.

Authors:  G Weidt; W Deppert; S Buchhop; H Dralle; F Lehmann-Grube
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

4.  Sensitization of MHC class I-restricted T cells to exogenous proteins: evidence for an alternative class I-restricted antigen presentation pathway.

Authors:  B Martinez-Kinader; G B Lipford; H Wagner; K Heeg
Journal:  Immunology       Date:  1995-10       Impact factor: 7.397

5.  CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer.

Authors:  Erin M Bange; Nicholas A Han; Paul Wileyto; Justin Y Kim; Sigrid Gouma; James Robinson; Allison R Greenplate; Madeline A Hwee; Florence Porterfield; Olutosin Owoyemi; Karan Naik; Cathy Zheng; Michael Galantino; Ariel R Weisman; Caroline A G Ittner; Emily M Kugler; Amy E Baxter; Olutwatosin Oniyide; Roseline S Agyekum; Thomas G Dunn; Tiffanie K Jones; Heather M Giannini; Madison E Weirick; Christopher M McAllister; N Esther Babady; Anita Kumar; Adam J Widman; Susan DeWolf; Sawsan R Boutemine; Charlotte Roberts; Krista R Budzik; Susan Tollett; Carla Wright; Tara Perloff; Lova Sun; Divij Mathew; Josephine R Giles; Derek A Oldridge; Jennifer E Wu; Cécile Alanio; Sharon Adamski; Alfred L Garfall; Laura A Vella; Samuel J Kerr; Justine V Cohen; Randall A Oyer; Ryan Massa; Ivan P Maillard; Kara N Maxwell; John P Reilly; Peter G Maslak; Robert H Vonderheide; Jedd D Wolchok; Scott E Hensley; E John Wherry; Nuala J Meyer; Angela M DeMichele; Santosha A Vardhana; Ronac Mamtani; Alexander C Huang
Journal:  Nat Med       Date:  2021-05-20       Impact factor: 87.241

6.  Autoantibodies produced spontaneously by young 1pr mice carry transforming growth factor beta and suppress cytotoxic T lymphocyte responses.

Authors:  D A Rowley; E T Becken; R M Stach
Journal:  J Exp Med       Date:  1995-05-01       Impact factor: 14.307

Review 7.  Antigen presentation to cytotoxic T lymphocytes in vivo.

Authors:  M J Bevan
Journal:  J Exp Med       Date:  1995-09-01       Impact factor: 14.307

8.  CD8 T cells compensate for impaired humoral immunity in COVID-19 patients with hematologic cancer.

Authors:  Alexander Huang; Erin Bange; Nicholas Han; E Paul Wileyto; Justin Kim; Sigrid Gouma; James Robinson; Allison Greenplate; Florence Porterfield; Olutosin Owoyemi; Karan Naik; Cathy Zheng; Michael Galantino; Ariel Weisman; Carolin Ittner; Emily Kugler; Amy Baxter; Madison Weirick; Christopher McAllister; Ngolela Esther Babady; Anita Kumar; Adam Widman; Susan Dewolf; Sawsan Boutemine; Charlotte Roberts; Krista Budzik; Susan Tollett; Carla Wright; Tara Perloff; Lova Sun; Divij Mathew; Josephine Giles; Derek Oldridge; Jennifer Wu; Cecile Alanio; Sharon Adamski; Laura Vella; Samuel Kerr; Justine Cohen; Randall Oyer; Ryan Massa; Ivan Maillard; Kara Maxwell; Peter Maslak; Robert Vonderheide; Jedd D Wolchok; Scott Hensley; E Wherry; Nuala Meyer; Angela DeMichele; Santosha Vardhana; Ronac Mamtani; Oluwatosin Oniyide; Roseline Agyekum; Thomas Dunn; Tiffanie Jones; Heather Giannini; Alfred Garfall; John Reilly
Journal:  Res Sq       Date:  2021-02-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.